Total Payments
$41,080
2024 Payments
$58.60
Companies
5
Transactions
41
Medicare Patients
1,147
Medicare Billing
$120,950
Payment Breakdown by Category
Consulting$34,923 (85.0%)
Other$3,030 (7.4%)
Travel$2,219 (5.4%)
Food & Beverage$895.85 (2.2%)
Education$12.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $34,923 | 20 | 85.0% |
| Honoraria | $3,030 | 1 | 7.4% |
| Travel and Lodging | $2,219 | 8 | 5.4% |
| Food and Beverage | $895.85 | 11 | 2.2% |
| Education | $12.74 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $37,542 | 37 | $0 (2023) |
| Biogen, Inc. | $3,065 | 1 | $0 (2022) |
| Sarepta Therapeutics, Inc. | $370.00 | 1 | $0 (2019) |
| ARGENX US, INC. | $58.60 | 1 | $0 (2024) |
| NATUS MEDICAL INCORPORATED | $44.54 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58.60 | 1 | ARGENX US, INC. ($58.60) |
| 2023 | $1,100 | 1 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($1,100) |
| 2022 | $15,440 | 5 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($12,375) |
| 2021 | $4,813 | 4 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($4,813) |
| 2020 | $4,307 | 7 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($4,263) |
| 2019 | $11,167 | 17 | Mitsubishi Tanabe Pharma America, Inc. ($10,797) |
| 2018 | $4,182 | 5 | Mitsubishi Tanabe Pharma America, Inc. ($4,182) |
| 2017 | $12.74 | 1 | Mitsubishi Tanabe Pharma America, Inc. ($12.74) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/24/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $58.60 | General |
| Category: Immunology | ||||||
| 03/01/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | EXSERVAN (Drug), RADICAVA, RADICAVA ORS | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 10/20/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,065.00 | General |
| 06/02/2022 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 06/02/2022 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 03/03/2022 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $8,250.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 02/04/2022 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 11/04/2021 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 11/04/2021 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $962.50 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 08/11/2021 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 03/30/2021 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 11/24/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 09/03/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 06/30/2020 | NATUS MEDICAL INCORPORATED | — | Food and Beverage | In-kind items and services | $44.54 | General |
| 06/18/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 06/11/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $275.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 02/21/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $275.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 02/13/2020 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 10/14/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $5,637.50 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 10/14/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Travel and Lodging | Cash or cash equivalent | $65.30 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 10/01/2019 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: Genetic Disease | ||||||
| 09/03/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 08/17/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | In-kind items and services | $86.60 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 08/17/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | In-kind items and services | $62.99 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 08/17/2019 | Mitsubishi Tanabe Pharma America, Inc. | Radicava (Drug) | Food and Beverage | In-kind items and services | $62.29 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 253 | 314 | $159,479 | $26,058 |
| 2022 | 13 | 325 | 403 | $190,738 | $37,172 |
| 2021 | 9 | 294 | 386 | $140,006 | $33,563 |
| 2020 | 11 | 275 | 342 | $113,316 | $24,156 |
Total Patients
1,147
Total Services
1,445
Medicare Billing
$120,950
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 62 | $46,262 | $8,065 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 77 | $40,237 | $6,634 | 16.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 37 | 42 | $22,494 | $3,269 | 14.5% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 15 | 15 | $16,599 | $2,553 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $12,648 | $1,949 | 15.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 32 | $11,121 | $1,764 | 15.9% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 16 | 17 | $5,714 | $860.49 | 15.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 30 | $4,075 | $753.47 | 18.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 23 | 26 | $329.00 | $210.60 | 64.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 59 | $35,594 | $7,579 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 69 | $30,470 | $6,234 | 20.5% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 45 | 55 | $23,098 | $4,411 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $19,349 | $3,988 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 54 | $16,388 | $3,510 | 21.4% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 12 | 12 | $15,573 | $2,451 | 15.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 14 | 14 | $11,153 | $1,986 | 17.8% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 13 | 13 | $12,102 | $1,930 | 15.9% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 23 | 29 | $8,510 | $1,551 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $7,376 | $1,443 | 19.6% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 13 | 13 | $7,692 | $1,321 | 17.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 14 | 29 | $3,181 | $706.04 | 22.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 18 | 21 | $252.00 | $62.25 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 61 | 82 | $44,310 | $10,992 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 64 | 86 | $34,670 | $8,402 | 24.2% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 35 | 46 | $20,644 | $4,054 | 19.6% |
About Dr. David Walk, MD
Dr. David Walk, MD is a Neurology healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679674501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Walk, MD has received a total of $41,080 in payments from pharmaceutical and medical device companies, with $58.60 received in 2024. These payments were reported across 41 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($34,923).
As a Medicare-enrolled provider, Walk has provided services to 1,147 Medicare beneficiaries, totaling 1,445 services with total Medicare billing of $120,950. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuromuscular Medicine
- Location Minneapolis, MN
- Active Since 09/25/2006
- Last Updated 11/12/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1679674501
Products in Payments
- Radicava (Drug) $27,367
- RADICAVA (Drug) $9,075
- EXSERVAN (Drug) $1,100
- Exondys 51 (Drug) $370.00
- VYVGART (Drug) $58.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Minneapolis
Jeffrey Allen, M.d, M.D
Neurology — Payments: $940,553
Neurology $940,553
Jerrold Vitek, Md, MD
Neurology — Payments: $173,449
Neurology $173,449
Kamakshi Lakshminarayan, Md, MD
Neurology — Payments: $85,052
Neurology $85,052
Dr. Sanjay Singh, Md, MD
Neurology — Payments: $83,592
Neurology $83,592
Leonardo Brito De Almeida, M.d, M.D
Neurology — Payments: $54,552
Neurology $54,552
Byungkwan Hwang, M.d, M.D
Neurology — Payments: $24,593
Neurology $24,593